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Alzheimer's disease, Endoproteolytic cleavage, Huntington's disease, Prion disease A common event that occurs in these ND is the alteration of endoproteolytic cleavage due to genetic mutations of the associatedproteases or in the target substrate. Endoproteolytic cleavage resulting in protein truncation has significant effects on the structure and function of a protein representing a common feature of ND. In this review, we will discuss the endoproteolytic cleavage events that lead to ND, namely Alzheimer's disease, Huntington's disease and prion diseases.
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Overview of endoproteolytic cleavage
Endoproteolytic cleavage is the break down of proteins into smaller polypeptides or amino acids. This process is accelerated mainly through the action of proteases.
Under normal circumstance, proteolysis is the physiological function that provides nutrients to the organism it may serve as a means to control the activity of a protein after protein synthesis. This process is important for cellular homeostasis thus allowing the regulation of cellular processes as well as removing the build up of unwanted protein products that could be toxic to the cell. Not surprisingly, deregulation of endoproteolysis can result in a number of human diseases such as pancreatitis, diabetes mellitus, Alzheimer's disease (AD), prion diseases, emphysema, muscular dystrophy, to name a few. In this review, we shall focus on the deregulation of proteolysis in neurodegenerative diseases, namely Alzheimer's disease, Huntington's disease (HD), and Prion diseases. 
Alzheimer's disease
APP processing
Amyloid-β protein (Aβ) is mainly found in senile plaques. Aβ is generated from its precursor called amyloid precursor protein (APP) via sequential cleavage by the β-and γ-secretases [2] (Figure 1 ). Notably, genetic mutations observed in patients of mainly the inherited form of familial AD resulted in increased production or aggregation of Aβ, indicating that Aβ is a seed of AD pathogenesis. Specifically, the C-terminal region of Aβ shows diversity and the longer Aβ peptide is principally deposited in AD patient brains [3] . Therefore, the γ-secretase has become a major molecular target in drug discovery of AD. The putative APP γ-cleavage sites related to amino acid residues are located at the transmembrane domain (TMD). In fact, it has taken more than a decade of research to advance our current understanding of the γ-secretase, which performs endoproteolysis within the TMD [4] . Firstly, the genes to be identified by genetic analyses of the familial form of AD were those of the multispanning membrane protein encoding called presenilin (PS) 1 and 2 [5] . Remarkably, the missense mutations causing disease are likely to change γ-secretase cleavage of APP resulting in elevated production of aggregation-prone Aβ-form (Aβ42) as compared with the other main Aβ species, Aβ40 [6, 7] . Secondly, the ablation of presenilin eliminated cleavage by the γ-secretase cleavage of APP [8, 9] and the intramembrane aspartates found in PS TMD-6 and TMD-7 are necessary for Aβ production [10] . A number of cross-linking approaches showed that γ-secretase inhibitors (GSIs) directly implicated and targeted the PS proteins [11, 12] . Lastly, the perturbed function of the clathrin assembly lymphoid myeloid leukaemia protein gene (CALM) that is encoded by the phosphatidylinositol binding clathrin assembly protein (PICALM) was shown to cause alteration of the lysosomal localisation of the γ-secretase and in turn the production of Aβ42 [13, 14] . These studies demonstrate that PS possesses the catalytic activity resulting in γ-secretase intramembrane cleavage of APP, thus affecting AD pathogenesis.
PS is part of a family of intramembrane proteases (IMP) that are distinguished by the topology of their transmembrane domain and also by the nature of the membrane active site amino acid residues. The aspartate IMPs are located near two catalytic aspartate amino acid residues found in PSs, signal peptide peptidase (SPP), and SPP-like (SPPL) proteases [15, 16] . The catalytic aspartate of IMPs is located within the Gly-X-Gly-Asp motif and, hence, these proteases are known as the GXGDtype proteases [17] . The GXGD motif is conserved in type 4 prepilin peptidase proteins, and is prerequisite to many bacterial protease cleavages. Interestingly, SPP was originally identified by a chemical biology approach and contains the same GXGD motif but differs according to its primary sequence and topology [18] .
Nevertheless, the expression of PS alone is not sufficient to reconstitute the γ- 
Tau protein and neurofibrillary tangles
The other contributing factor to AD is the emergence of tau protein snarls found in neurofibrillary tangles that accumulate in AD and other dementias. Increasing evidence suggests that the soluble form of tau causes the most damage in neurodegeneration [27]. On one hand, a study has shown that tau 'stickiness' is because of its ability to aggregate that contributes to its toxicity [28] .
Tau truncation
Tau protein is naturally an intrinsically disordered protein singly encoded by In the eukaryotic cell, the MT cytoskeleton is an important network that plays a pivotal role in many cellular processes such as motility, morphogenesis, mitosis, meiosis, and the trafficking of organelles and macromolecules. The major constituent of MTs is the heterodimer of α-and β-tubulin proteins. The nature of MTs is highly dynamic showing a non-equilibrium behaviour often termed dynamic instability [38] .
The MTs adopt rapid stochastic transition through growth and shortening as an effect of the interaction of the heterodimer of tubulin dimers at its ends. This provides a mechanism for Tau protein to promote tubulin polymerisation and thus stabilize MTs [39] [40] [41] . The functional role of tau was initially shown to promote the assembly and stability of MTs [39] and to associate with the cytoskeleton. Tau interacts strongly with MTs [42] , and after associating with the MT via the repeat regions, stabilizes the MTs at the plus end, thus providing stability to the MTs during growth phases, whilst tau N-terminal domain may act as a 'spacer' region between tau and the MTs ensuring the correct distance between them [43] [44] [45] [46] . Also, there are a number of studies which implicate and corroborate that tau enhances the stabilization and assembly MTs on one hand, and tau mutations alter the association of tau with MTs on the other hand. For example, tau mutations such as G272V, DK280, P301L, P301S, L315R, G335V, V337M, and R406W alter tau's ability to interact with the MTs affecting MT assembly with a direct affect upon the cytoskeleton and all the activities associated with this network [44, [47] [48] [49] [50] [51] . This could be due to an alteration in the phosphorylation status of tau that could be essential to regulate tau-MT interactions [52, 53] , and, at the same time, to changes to the domain structure of the MT-binding site.
Several cellular factors have been reported to affect tau aggregation, such as post-translational modifications including phosphorylation and acetylation (see review for further information [54, 55] ), and proteolysis, including the molecular chaperone machinery. Tau proteolytic cleavage could play an important role in tau aggregation. Caspases-3 and -6 can cleave tau at amino residue sites D421 and D348
but caspase 3 has a greater efficiency [56] . In fact, tau cleavage site at D421 has already been observed in AD patient brains [56] [57] [58] . Furthermore, truncation of tau at D421 site accelerates tau aggregation compared to tau full length form [56] and this could act as a seed to initiating the process of aggregation of wild-type tau, as a mechanism prior to tangle formation [59, 60] . Tau cleavage by caspase does not impede hyperphosphorylation since both tau phosphorylation and truncation modifications are found in the brain of AD patients [56] . Tau phosphorylation slows its proteolytic processing and conversely its de-phosphorylation facilitates its clearance [61] . Furthermore, the D421-cleaved tau form can be phosphorylated by GSK3β [59] .
In addition to caspase cleavage, tau can be cleaved by other types of proteases including cathepsins, calpains, and thrombin [60, [62] [63] [64] . Pre-aggregated Aβ treatment results in tau truncation by calpain 1 generating a tau fragment 45 -230 amino acids (aa) [60] that is commonly found in many tauopathies [65] . This fragment (45-230 aa) of tau is particularly neurotoxic whilst other fragments generated by the calpain 2 protease are neuroprotective [60, 66] through their ability to form aggregates when arachodonic acid is present, thus perturbing aggregation of tau full length [65] . Recent studies have shown that tau could be cleaved by another type of protease called asparagine endopeptidase (AEP) also known as legumain (LGMN). AEP is a cysteine protease located in the lysosomes, which cleaves its substrates within the C-terminal region of the asparagine [67, 68] . The AEP protease is auto-activated and involves the removal of both C-and N-terminal pro-peptides at varying pH levels [69] . Tau protein undergoes cleavage by AEP at positions N255 and N368 [70] . This cleavage gives rise to several fragments that are unable to bind to MTs but can efficiently aggregate through the exposure of aggregation-prone tau residues i.e. 275-280 and 306-311 [70] . These tau AEP-cleaved fragments are readily hyperphosphorylated [70] . Altogether, these studies demonstrate that tau can be cleaved by many proteases and the fragments generated may promote aggregation and toxicity, thus contributing to the pathological events in AD.
Huntington's disease (HD)
Huntington's disease (HD) is a progressive inherited neurodegenerative disease which results in motor, cognitive and psychiatric symptoms [71] . HD is triggered by the expansion of the CAG repeat on chromosome 4 that encodes glutamine in the Nterminal of huntingtin (Htt) [72] . The normal Htt gene has less than 36 CAG repeats whilst the abnormal Htt gene has more than 36 CAG repeats. For HD, the disease starts in the striatum in medium-spiny neurons and later penetrates deep into the cortex [71] . Htt protein is widely expressed in the CNS and in other non-neuronal tissues [73] and dispersed throughout the intracellular compartments [74] [75] [76] . The human Htt protein is a large protein with a molecular weight of 350 kDa and with 3144 aa. It is made up of several domains including the HEAT (Htt, elongation factor 3, the PR65/A subunit of protein phosphatase 2A and the lipid kinase Tor) domains that are 50 aa in length and consist of 2 anti-parallel α-helices that form a hairpin that is important for protein-protein interactions (Fig. 3) . Approximately, 16 HEAT repeat domains have been found in Htt gene, which are arranged into clusters of 4 [77, 78] .
The role and function of the HEAT domains for Htt is unknown. In addition, Htt contains 4 PEST sequences where the name is derived from P (proline), E (glutamic acid), S (serine) and T (threonine) serving as signals for protein degradation by the proteasome [79] .
Htt interacts with a number of proteins that play a role in apoptosis, vesicle transport, endocytosis, morphogenesis, cell signalling and transcriptional regulation. The function of Htt is believed to act as a scaffolding protein i.e. a bridge bringing its interacting partners in close proximity to allow signals to be transferred [80] .
Interestingly, Htt has been shown to elevate the production of brain-derived neurotrophic factor (BDNF), a growth factor produced by striatal neurons [81] .
Proteolysis in Huntington's disease (HD)
Htt protein is proteolytically cleaved at many sites generating several N-terminal fragments. Htt can be cleaved by several proteases including calpain, caspases, AEPs and matrix metalloproteases. Htt contains 2 calpain sites located at positions 469 and 536 aa [82, 83] (Figure 3 ). Htt can be cleaved by several caspases such as caspase 3 at positions 513 and 552 aa [84, 85] , caspase 2 at 552 aa [86] and by caspase 6 at 586 aa [85] . The matrix metalloproteinase MMP-10 cleaves the Htt protein at 402 aa and is active in mice with HD [87] . The presence of the Htt fragments, where the cleavage sites have been mutated, promote lower toxicity of Htt indicating that proteolytic processing of Htt could contribute to HD pathogenesis [84, 88, 89] . Hence the proteolytic processing of Htt resulting in the generation of N-terminal fragments that contain polyglutamine tract could be a necessary stage in HD progression. This is due to N-terminal fragments which are more prone to aggregation and promote toxicity.
These N-terminal fragments have been demonstrated to be present both in the mouse HD models and in the brains of HD human patients [83, 90, 91] . HD progression in HD mouse model have shown to be perturbed through the development of protease inhibitors or by mutating specific sequences important in Htt protease cleavage [85, 88] . However, the task to prevent all the proteolytic cleavages of Htt is difficult through the use of protease inhibitors and represents a therapeutic challenge for drug discovery. Future efforts should be targeted to identify the specific roles of proteases and the effects of N-terminal truncated fragments of Htt on HD progression and their implications in the pathological process.
Prion diseases
Prion diseases such as Creutzfeldt-Jakob disease in humans, scrapie in sheep and bovine spongiform encephalopathy in cattle, are all infectious and potentially fatal neurological conditions as a result of misfolding of cellular prion protein (PrP  C ) converted into a structurally different β-sheet-rich pathogenic isoform (PrP Sc ) that is partially resistant to proteinase-K treatment and tend to aggregate [92] . The PrP C has a bipartite structure, N-terminal domain is disordered whilst the C-terminal domain is more structured containing 3 α-helices and 2 β-strands [93] . The function of PrP C is not clear but most studies indicate that PrP C could provide neuroprotection and it is a neurotrophic protein [94] . Neuroprotective function of PrP C has been demonstrated in many in vitro and in vivo studies [95, 96] . These studies showed that the expression of PrP C was sufficient to slow down cell death and, in several other expression studies, PrP C was shown to prevent cell death in stress conditions of serum deprivation of neurons [97] . Follow up studies have provided much evidence for PrP C implication in cellular survival as well as regulation of cell growth, proliferation, differentiation and stem cell expansion [98, 99] .
Proteolysis in Prion diseases
PrP C associates with the plasma membrane through a glycosyl-phosphatidylinositol (GPI) anchor. Early on after translocation into the endoplasmic reticulum, the Nterminal signal peptide is removed by signal peptidase followed by cleavage of the Cterminal hydrophobic domain (residues 231-253) before the attachment of a GPI anchor to the C-terminus. PrP C undergoes at least three proteolytic cleavage events after trafficking through the secretory pathway to the plasma membrane [100] . At the plasma membrane or in the endosomes, PrP C can be cleaved by α-cleavage at position 110-111 and 112 aa to yield two products: (i) PrP C1 , a product of 17kDa containing the GPI-anchor C-terminal fragment, and (ii) a 11kDa N-terminal fragment that is released from the cell into the extracellular space (Figure 4 ). α-cleavage was first
shown for the chicken PrP [101] and then in later studies shown in samples from humans [102] . The protease responsible for the α-cleavage of PrP C is still unknown but is currently known as the α-PrPase [103] . However, the ADAM (A Disintegrin And Metalloprotease) family could be involved in the α-cleavage of PrP. ADAM10
and ADAM17 (also known as TACE) are implicated [104] in the α-cleavage of PrP.
Also, ADAM9 [105] and ADAM8 [106] found in muscle could also be involved in α-cleavage [107] . There still remains some controversy as to which protease is directly involved and how this process is regulated [107] . It is thought that the cleavage event occurs in the endosome [108] or the late endocytic pathway [109] . α-cleavage occurs in normal brains with approximately 50% of C1 present compared to full length PrP [102] . PrP C can also undergo β-cleavage by a calpain protease at position 89-90 aa to produce PrP C2 , a 20kDa fragment containing the GPI-anchor and also a smaller 8kDa fragment known as PrPN2. β-cleavage of PrP C is a pathological event occurring at the plasma membrane in prion diseases which is promoted during conditions of oxidative stress such as the presence of reactive oxygen species. Also, some of PrP C is shed constitutively at the plasma membrane by the zinc metalloprotease called ADAM10 [100] . Most evidence indicates that α-cleavage of PrP has a neuroprotective function as opposed to contributing to prion diseases. In contrast, β-cleavage generates the PrP C2 fragment that is sufficient to support prion disease and appears to be abundant in the brains of prion-diseased individuals than in healthy ones [102] , indicating that β-cleavage could contribute to prion diseases. However, it is likely that both types of cleavage have a role in prion disease but α-cleavage prevents PrP from converting into PrPSc.
Concluding remarks
Human NDs such as AD, HD and prion diseases are characterized by neurodegeneration that leads to a progressive functional decline. More than 20 million people worldwide are suffering from ND each year. The number of individuals with
NDs is increasing rapidly due to lack of effective therapies. Thus, novel efficient therapy for ND is foremost unmet health need. NDs such as AD, HD and prion diseases greatly differ in respect of their clinical manifestation, duration, onset, etc.
Altogether, these human diseases share numerous common features such as altered protein cleavage, protein aggregation, oxidative stress, etc. The major pathological event that is crucial and shared by many NDs such as AD, HD and prion diseases is proteolytic cleavage of disease-modifying proteins. Emerging current evidence suggests that protein truncation not only acts as the driving force behind ND but also serves as a seed for regeneration of novel truncated forms that finally speed up the aggregation process leading to oligomeric assemblies of Htt and PrP, amyloid plaque, and neurofibrillary tangles formation. To this end, we need to concentrate our efforts towards understanding the endoproteolytic processes and how to perturb these proteases without affecting cellular homeostasis. Disordered NMR structure Globular NMR structure Calpain β-cleavage sites G74/Q95 to S103/K104 Unknown protease α-cleavage sites K110/H111 and M112 
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